News & Events

  • Elrig UK’s Drug Discovery 2021

    When: Oct. 19th, 2021 to Oct. 20th, 2021

    Anima Biotech has been invited to present at Elrig UK’s Drug Discovery 2021 meeting, taking place in Liverpool, U.K. Iris Alroy, Ph.D., Vice President of Research and Development at Anima Biotech, will give a presentation titled, “mRNA Lightning platform for the discovery of selective small molecule mRNA regulatory drugs.” Elrig’s annual Drug Discovery meeting is one of Europe’s largest gatherings for life science industry professionals and serves as a platform for the whole drug discovery community to re-connect with colleagues, re-invent the process of drug discovery and re-imagine a new vision for drug discovery.

    Visit the conference website »

  • Industry (SCI)’s “RNA as a Target For The Life Sciences”

    When: Oct. 12th, 2021 to Oct. 13th, 2021

    Anima Biotech has been invited to present at SCI’s “RNA as a target for the life sciences” event, taking place virtually this year. Iris Alroy, Ph.D., Vice President of Research and Development at Anima Biotech, will give a presentation titled, “mRNA translation modulators binding to novel targets: from mRNA processing to mRNA translation”, followed by her participation in a panel. The event will feature global leaders and leading experts in RNA technology to discuss current and future aspects of this field. In addition to Anima’s presentation, Jason Tierney, Senior Medicinal Scientist of Anima Biotech, will be chairing sessions alongside some of the distinguished organizing committee members.

    Download Press Release »

    Visit the conference website »

  • Sachs Associates 21st Annual Biotech in Europe Forum (BEF)

    When: Oct. 7th, 2021 to Oct. 8th, 2021

    Anima Biotech has been invited to participate during the virtual 21st Annual Biotech in Europe Forum (BEF) hosted by Sachs Associates. Yochi Slonim, Co-founder and CEO, will serve as an expert on the “Platform Technologies & Novel Therapeutics” panel. The event will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 15 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities.

    Visit the conference website »

  • UBS Biotechnology Private Company Symposium

    When: Sep. 22nd, 2021

    Anima Biotech has been invited to give a presentation during the UBS Biotechnology Private Company Symposium. Yochi Slonim, Co-founder and CEO, will provide a corporate update to those registered for the conference. At more than 300 conferences a year across Europe, Asia Pacific and the Americas, UBS connects corporate leaders and the global investor community, influential policy makers and industry experts. UBS’ award-winning analysts and economists debate the big ideas, trends and challenges shaping the environment, bringing attendees local knowledge with global perspective.  

    Download Press Release »

  • 3rd Annual RAS-Targeted Drug Development Summit

    When: Sep. 21st, 2021 to Sep. 23rd, 2021

    Anima Biotech has been invited to participate on an expert panel during the 3rd Annual RAS-Targeted Drug Development meeting. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will participate as an expert on a panel titled, “Exploring Chemistry Between Mutations: How to Exploit Mutations for Selective Targeting.” This year’s meeting will mark the largest summit in the RAS series to date. After decades of R&D efforts into targeted KRAS therapies, this year’s summit will serve as an all-inclusive program addressing emerging strategies to target all RAS mutations, robust and effective combination strategies and shining a spotlight onto optimized clinical translation and clinical trials in progress.

    Download Press Release »

    Visit the conference website »

  • Undruggable Leaders Forum

    When: Sep. 15th, 2021 to Sep. 16th, 2021

    Anima Biotech has been invited to participate in the 2021 Undruggable Leaders Forum. Yochi Slonim, CEO, will serve as an expert during a fireside chat alongside Beth Shafer, Head of Neuroscience, Drug Discovery Sciences and Externalization Business Development at Takeda. This session will explore Anima-Takeda collaboration for the discovery and development of mRNA translation modulators for Neurological diseases. The Undruggable Leaders Forum was established with the mission of uniting key experts to discuss the latest scientific developments and clinical breakthroughs in diseases currently deemed “undruggable.”

    Download Press Release »

    Visit the conference website »

  • 5th IPF Summit 2021

    When: Aug. 25th, 2021 to Aug. 27th, 2021

    Anima Biotech has been invited to give a presentation at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit. Iris Alroy, Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Multiple mechanisms for Collagen mRNA translation regulation in IPF: from mRNA processing to mRNA translation.” The 5th IPF Summit will be an opportunity to learn from industry experts and gain the knowledge needed to tackle tough translational and clinical hurdles to ultimately develop more reliable, effective and disease modifying IPF drugs. Speakers will present innovative research and provide updates on state-of-the-art science to make meaningful impact on the lives of the 3 million patients suffering with IPF worldwide.

  • Anima Biotech achieves first milestone in Takeda collaboration

    The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles
    Anima to an undisclosed milestone payment.

    “Since announcing our partnership with Anima back in March, our research collaboration has kicked off to a success with the achievement of this first milestone,” said Ceri Davies Head, Neuroscience Drug Discovery Unit at Takeda.

    “We are delighted to announce this successful milestone in our strategic collaboration with Takeda which demonstrates the advantage of our approach with small molecule mRNA drugs. We are highly motivated to keep advancing the Huntington’s Disease program and the overall collaboration” said Yochi Slonim, Anima’s co-founder & CEO.

  • UBS Innovation Series: The Next Wave in Neurodegeneration

    When: Jun. 3rd, 2021

    Anima Biotech has been invited to participate in a presentation at the UBS Innovation Series: The Next Wave in Neurodegeneration. The presentation by Yochi Slonim, CEO, will feature Anima Biotech’s proprietary technology platform and its use in developing mRNA translation modulators for neurodegenerative disorders, such as Alzheimer’s disease. The virtual conference will shed light on the latest advancements in neurodegeneration.

  • Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs

    When: May. 18th, 2021 to May. 19th, 2021

    Anima Biotech has been invited to participate in both a presentation and a live panel discussion at the Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs Conference. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting mRNA Translation in a Tissue Selective and Disease-Specific Manner with Small Molecules.” Additionally, Dr. Alroy will serve as an expert on a panel during the virtual meeting. The conference was established to highlight some of the innovative approaches being pursued to find new small molecule drugs for targeting RNA for therapeutics intervention.

    Visit the conference website »

Pages